ChemoCentryx, Inc. (NASDAQ:CCXI) is reporting third quarter financial results on Monday 9th November 2020, after market close.
According to analysts surveyed by Thomson Reuters, CCXI is expected to report 3Q20 loss of $ 0.31 per share from revenue of $ 10.70 million.
For the full year, analysts anticipate top line of $ 74.95 million, while looking forward to loss of $ 0.73 per share bottom line.
Previous Quarter Performance
ChemoCentryx, Inc. unwinded income for the second quarter of $ 0.29 per share, from the revenue of $ 49.44 million. The quarterly revenues improved 589.54 percent compared with the same quarter last year. Street analysts expected ChemoCentryx, Inc. to report loss of $ 0.34 per share on revenue of $ 8.25 million for the second quarter. The bottom line results beat street analysts by $ 0.63 or 185.29 percent, at the same time, top line results outshined analysts by $ 41.19 million or 499.27 percent.
Stock Performance
On Friday, shares of ChemoCentryx, Inc. has traded high as $ 55.35 and has cracked $ 53.14 on the downward trend, reaching $ 54.99 with volume of 399.90 thousand shares.
According to the previous trading day, closing price of $ 54.99, representing a 592.51 % increase from the 52 week low of $ 7.88 and a 16.6 % decrease over the 52 week high of $ 65.43.
The company has a market capital of $ 3.79 billion and is part of the Healthcare sector and Biotechnology industry.
Conference Call
ChemoCentryx, Inc. will be hosting a conference call at 5:00 PM eastern time on 9th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.chemocentryx.com
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis.
